Absci (ABSI) closed at $8.45 on November 13, 2026, down 7.5% from the previous close, on volume of 5,232,127 shares (30-day average 3,882,610).
Data as of November 13, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Diagonal Call Spread | 20-Nov-26 : 15-Jan-273 : 4 C | 2,414 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Cathie Wood's weekly recap: boosts Nvidia, CoreWeave, Archer Aviation; pares Tempus AI, Palantir
Seeking Alpha News (Mon, 16-Nov 7:05 AM ET)
TipRanks (Fri, 13-Nov 9:40 AM ET)
H.C. Wainwright Keeps Their Buy Rating on AbSci (ABSI)
TipRanks (Fri, 13-Nov 9:40 AM ET)
Absci Earnings Call: Hair-Loss Data Nears
TipRanks (Thu, 12-Nov 7:21 PM ET)
AbSci Reports Third-Quarter Results and Business Updates
TipRanks (Thu, 12-Nov 7:52 AM ET)
Absci GAAP EPS of -$0.19 in-line, revenue of $0.3M misses by $0.28M
Seeking Alpha News (Thu, 12-Nov 7:12 AM ET)
Absci Reports Business Updates and Third Quarter 2026 Financial and Operating Results
Globe Newswire (Thu, 12-Nov 7:05 AM ET)
Globe Newswire (Thu, 12-Nov 7:00 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 11-Nov 6:00 PM ET)
Absci Q3 2026 Earnings Preview
Seeking Alpha News (Wed, 11-Nov 11:00 AM ET)
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.
Absci trades on the NASDAQ stock market under the symbol ABSI.
As of November 16, 2026, ABSI stock price declined to $7.77 with 1,851,379 million shares trading.
ABSI has a beta of 1.77, meaning it tends to be more sensitive to market movements. ABSI has a correlation of 0.05 to the broad based SPY ETF.
ABSI has a market cap of $1.33 billion. This is considered a Small Cap stock.
Last quarter Absci reported $304,000 in Revenue and -$.19 earnings per share. This fell short of revenue expectation by $-687,360 and met earnings estimates .
In the last 3 years, ABSI traded as high as $12.54 and as low as $1.28.
The top ETF exchange traded funds that ABSI belongs to (by Net Assets): ARKG, VTI, XBI, IWM, VXF.
ABSI has outperformed the market in the last year with a return of +194.3%, while the SPY ETF gained +11.8%. However, in the most recent history, ABSI shares have underperformed the stock market with its stock returning -17.9% in the last 3 month period and -30.2% for the last 2 week period, while SPY has returned -4.1% and -1.6%, respectively.
ABSI support price is $7.84 and resistance is $9.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABSI shares will trade within this expected range on the day.